Postoperative 3D conformal radiation therapy with dose-volume histogram assessment in non small-cell lung cancer
Détails
ID Serval
serval:BIB_C9A972CD5FE4
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Postoperative 3D conformal radiation therapy with dose-volume histogram assessment in non small-cell lung cancer
Titre de la conférence
49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology
Adresse
Los Angeles, United-States, October 28-November 1, 2007
ISBN
0360-3016
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
69
Série
International Journal of Radiation Oncology Biology Physics
Pages
S498-S499
Langue
anglais
Notes
Meeting Abstract
Résumé
Purpose/Objective(s): Despite many randomized trials, the indication of postoperative radiation therapy (PORT) in non small cell
lung cancer (NSCLC) is controversial. Involved-field conformal (3D) RT has never been studied prospectively. In this study, we
aim to assess the outcome of patients treated with involved-field 3D PORT with or without chemotherapy in locally advanced
NSCLC.
Materials/Methods: From 1990 to 2006, data from 75 consecutive patients treated with curative surgery and PORT for NSCLC
were retrospectively analyzed. Male to female ratio was 57/18, and median age was 58 years (38-76). There were 5 patients with
stage I, 22 with stage II, and 48 with stage III disease. Pneumonectomy or lobectomy was realized in 24 and 51 patients, respectively.
Mediastinal lymphadenectomy was performed in all patients. PORT indications were positive margins and/or positive mediastinal
lymph nodes. Cisplatin-based chemotherapy was given in 15 patients. All patients had 3D conformal planning. Median
RT dose was 60 Gy using at least 6-MV photons in 6 weeks, and CTV included bronchial stump and only positive nodal areas.
Dose-volume histograms (DVH) assessing the pulmonary volume receiving 20 Gy (V20 Gy) were used in all patients.
Results: Compliance to PORT was 100%. In a median follow-up period of 55 months, 26 (35%) patients are alive without disease.
Median overall survival time was 24 months, with survival rate of 35% at 5 years (Fig. 1). The 5-year locoregional control and
distant disease-free rates were 80% and 57%, respectively. Patients treated with pneumonectomy and those treated with at least
60-Gy PORT had better outcome (Fig. 2). Grade 3 or more CTC v3.0 toxicity was observed only in 4 (5%) pts. No lethal toxicity
was observed.
Conclusions: We conclude that involved-field 3D conformal 60-Gy PORT tailored with DVH V20 Gy assessment improves
locoregional control without increasing lethal toxicity. Prospective studies using the above-mentioned criteria are warranted.
lung cancer (NSCLC) is controversial. Involved-field conformal (3D) RT has never been studied prospectively. In this study, we
aim to assess the outcome of patients treated with involved-field 3D PORT with or without chemotherapy in locally advanced
NSCLC.
Materials/Methods: From 1990 to 2006, data from 75 consecutive patients treated with curative surgery and PORT for NSCLC
were retrospectively analyzed. Male to female ratio was 57/18, and median age was 58 years (38-76). There were 5 patients with
stage I, 22 with stage II, and 48 with stage III disease. Pneumonectomy or lobectomy was realized in 24 and 51 patients, respectively.
Mediastinal lymphadenectomy was performed in all patients. PORT indications were positive margins and/or positive mediastinal
lymph nodes. Cisplatin-based chemotherapy was given in 15 patients. All patients had 3D conformal planning. Median
RT dose was 60 Gy using at least 6-MV photons in 6 weeks, and CTV included bronchial stump and only positive nodal areas.
Dose-volume histograms (DVH) assessing the pulmonary volume receiving 20 Gy (V20 Gy) were used in all patients.
Results: Compliance to PORT was 100%. In a median follow-up period of 55 months, 26 (35%) patients are alive without disease.
Median overall survival time was 24 months, with survival rate of 35% at 5 years (Fig. 1). The 5-year locoregional control and
distant disease-free rates were 80% and 57%, respectively. Patients treated with pneumonectomy and those treated with at least
60-Gy PORT had better outcome (Fig. 2). Grade 3 or more CTC v3.0 toxicity was observed only in 4 (5%) pts. No lethal toxicity
was observed.
Conclusions: We conclude that involved-field 3D conformal 60-Gy PORT tailored with DVH V20 Gy assessment improves
locoregional control without increasing lethal toxicity. Prospective studies using the above-mentioned criteria are warranted.
Web of science
Création de la notice
28/04/2008 11:35
Dernière modification de la notice
20/08/2019 16:44
Données d'usage
